Bicalutamide Does Not Raise Transaminases Compared to Alternative Anti-Androgen Regimens Among Transfeminine Adolescents and Young Adults: A Retrospective Cohort Study
February 2024
Studysummary In this study, bicalutamide at low doses was not linked to significant liver enzyme changes compared to other androgen-blocking treatments in transfeminine adolescents and young adults, suggesting its safety with careful monitoring for this population over one year.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on medrxiv.org →